Guardant Health Leads the Way in Blood-Based Single Cancer Screening

Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer, or CRC. Although these are promising markets with multi-billion-dollar revenue potential, it is still the early days with considerable uncertainty surrounds the details of payer coverage and guideline inclusion. We do not expect the company to generate positive cash flows until 2028.